{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:38:51Z","timestamp":1761223131483,"version":"build-2065373602"},"reference-count":138,"publisher":"Elsevier BV","issue":"19-20","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012359","name":"Promotion and Mutual Aid Corporation for Private Schools of Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.drudis.2010.08.001","type":"journal-article","created":{"date-parts":[[2010,8,12]],"date-time":"2010-08-12T04:59:08Z","timestamp":1281589148000},"page":"826-841","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents"],"prefix":"10.1016","volume":"15","author":[{"given":"Punniyakoti T.","family":"Veeraveedu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh S.","family":"Palaniyandi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken\u2019ichi","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Komai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajarajan A.","family":"Thandavarayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijayakumar","family":"Sukumaran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2010.08.001_bib0005","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/01.CIR.73.2.257","article-title":"Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe chronic heart failure","volume":"73","author":"Lee","year":"1986","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0010","first-page":"72","article-title":"The outcome of hyponatremia in a general hospital population","volume":"22","author":"Baran","year":"1984","journal-title":"Clin. Nephrol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0015","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1071-9164(99)91339-8","article-title":"Vasopressin: a therapeutic target in congestive heart failure?","volume":"5","author":"Goldsmith","year":"1999","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0020","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0002-8703(02)94708-3","article-title":"Vasopressin: a new target for the treatment of heart failure","volume":"146","author":"Lee","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2010.08.001_bib0025","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coph.2003.06.005","article-title":"Vasopressin receptor antagonists in heart failure","volume":"3","author":"Thibonnier","year":"2003","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0030","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1210\/jcem-59-5-924","article-title":"Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis","volume":"59","author":"Lilly","year":"1984","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2010.08.001_bib0035","doi-asserted-by":"crossref","first-page":"2B","DOI":"10.1016\/j.amjcard.2005.03.002","article-title":"Hyponatremia in congestive heart failure","volume":"95","author":"Oren","year":"2005","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1111\/j.1527-5299.2006.04844.x","article-title":"Hyponatremia and heart failure \u2013 treatment considerations","volume":"12","author":"Sica","year":"2006","journal-title":"Congest. Heart Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0045","first-page":"H2245","article-title":"Effects of oral AVP receptor antagonists OPC-21268 and OPC-31260 on congestive heart failure in conscious dogs","volume":"267","author":"Naitoh","year":"1994","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0050","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0008-6363(01)00288-7","article-title":"The role of V2 vasopressin antagonists in hyponatremia","volume":"51","author":"Palm","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2010.08.001_bib0055","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1161\/01.HYP.26.5.828","article-title":"Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism","volume":"26","author":"Burrell","year":"1995","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2010.08.001_bib0060","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1161\/01.HYP.23.6.737","article-title":"Blood pressure-lowering effect of an orally active vasopressin V1 receptor antagonist in mineralocorticoid hypertension in the rat","volume":"23","author":"Burrell","year":"1994","journal-title":"Hypertension"},{"key":"10.1016\/j.drudis.2010.08.001_bib0065","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","article-title":"Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist","volume":"9","author":"Gattone","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2010.08.001_bib0070","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/ki.1993.207","article-title":"Therapeutic efficacy of non-peptide ADH antagonist OPC-31260 in SIADH rats","volume":"44","author":"Fujisawa","year":"1993","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2010.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1210\/jcem.82.4.3900","article-title":"Acute aquaresis by the nonpeptide arginine vasopressin (AVP) antagonist OPC-31260 improves hyponatremia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"82","author":"Saito","year":"1997","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2010.08.001_bib0080","doi-asserted-by":"crossref","first-page":"413","DOI":"10.7326\/0003-4819-96-4-413","article-title":"Role of vasopressin in abnormal water excretion in cirrhotic patients","volume":"96","author":"Bichet","year":"1982","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.drudis.2010.08.001_bib0085","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/jop.2000.16.203","article-title":"Effect of SR121463, a selective non-peptide vasopressin V2 receptor antagonist, in a rabbit model of ocular hypertension","volume":"16","author":"Lacheretz","year":"2000","journal-title":"J. Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0090","doi-asserted-by":"crossref","first-page":"14B","DOI":"10.1016\/j.amjcard.2005.03.004","article-title":"Current treatments and novel pharmacologic treatments for hyponatremia in congestive heart failure","volume":"95","author":"Goldsmith","year":"2005","journal-title":"Am. J. Cardiol."},{"issue":"Suppl. 7","key":"10.1016\/j.drudis.2010.08.001_bib0095","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/00005344-198600087-00011","article-title":"Chronic blockade of vasopressin receptors in rats","volume":"8","author":"Hofbauer","year":"1986","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0100","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0022-3565(25)24091-5","article-title":"Biologic response to chronic blockade of vasopressin receptors in Sprague\u2013Dawley rats","volume":"245","author":"Mah","year":"1988","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0105","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/0002-9149(85)90743-X","article-title":"Acute hemodynamic effect of a vascular antagonist of vasopressin in patients with congestive heart failure","volume":"55","author":"Nicod","year":"1985","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0110","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/978-1-4615-4871-3_53","article-title":"Recent advances in the understanding of water metabolism in heart failure","volume":"449","author":"Schrier","year":"1998","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/jme.0.0290001","article-title":"Vasopressin V2 receptor antagonists","volume":"29","author":"Verbalis","year":"2002","journal-title":"J. Mol. Endocrinol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0120","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0022-3565(24)36784-9","article-title":"Pharmacological profile of YM087, a novel potent nonpeptide vasopressin V1A and V2 receptor antagonist, in vitro and in vivo","volume":"282","author":"Tahara","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0125","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/S0014-2999(96)00940-5","article-title":"Pharmacological profile of YM087, a novel nonpeptide dual vasopressin V1A and V2 receptor antagonist, in dogs","volume":"321","author":"Yatsu","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0130","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1046\/j.1440-1681.1999.03045.x","article-title":"Pharmacological profile of orally administered YM087, a vasopressin antagonist, in conscious rats","volume":"26","author":"Tomura","year":"1999","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0135","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1021\/jm980179c","article-title":"5-Fluoro-2-methyl-N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-3-chlorophenyl]benzamide (VPA-985): an orally active arginine vasopressin antagonist with selectivity for V2 receptors","volume":"41","author":"Albright","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.drudis.2010.08.001_bib0140","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.1172\/JCI119098","article-title":"Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist","volume":"98","author":"Serradeil-Le Gal","year":"1996","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2010.08.001_bib0145","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0022-3565(24)37873-5","article-title":"OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats","volume":"287","author":"Yamamura","year":"1998","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0150","first-page":"F321","article-title":"Osmotic and nonosmotic control of vasopressin release","volume":"236","author":"Schrier","year":"1979","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0155","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1152\/physrev.1988.68.4.1248","article-title":"Role of vasopressin in cardiovascular regulation","volume":"68","author":"Share","year":"1988","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.drudis.2010.08.001_bib0160","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1507\/endocrj.44.311","article-title":"Interaction of osmotic and nonosmotic stimuli in regulation of vasopressin secretion in hypoosmolar state of man","volume":"44","author":"Kamoi","year":"1997","journal-title":"Endocr. J."},{"key":"10.1016\/j.drudis.2010.08.001_bib0165","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S1521-690X(03)00049-6","article-title":"Disorders of body water homeostasis","volume":"17","author":"Verbalis","year":"2003","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2010.08.001_bib0170","first-page":"R249","article-title":"Plasma vasopressin response to peripheral administration of angiotensin in conscious rats","volume":"248","author":"Yamaguchi","year":"1985","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0175","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.brainresbull.2006.09.002","article-title":"Involvement of anteroventral third ventricular AMPA\/kainate receptors in both hyperosmotic and hypovolemic AVP secretion in conscious rats","volume":"71","author":"Yamaguchi","year":"2006","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.drudis.2010.08.001_bib0180","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1042\/bst0070861","article-title":"Hormonal stimulation of phosphatidylinositol breakdown with particular reference to the hepatic effects of vasopressin","volume":"7","author":"Michell","year":"1979","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.drudis.2010.08.001_bib0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/S1043-2760(00)00304-0","article-title":"Vasopressin receptors","volume":"11","author":"Birnbaumer","year":"2000","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2010.08.001_bib0190","doi-asserted-by":"crossref","first-page":"3747","DOI":"10.1074\/jbc.273.6.3747","article-title":"Regulation of protein synthesis in ventricular myocytes by vasopressin. The role of sarcoplasmic\/endoplasmic reticulum Ca2+ stores","volume":"273","author":"Reilly","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.08.001_bib0195","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0022-2828(03)00053-1","article-title":"The role of arginine vasopressin and its receptors in the normal and failing rat heart","volume":"35","author":"Chandrashekhar","year":"2003","journal-title":"J. Mol. Cell. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0200","series-title":"Text Book of Medical Physiology","first-page":"308","article-title":"The kidneys and body fluids","author":"Guyton","year":"1996"},{"key":"10.1016\/j.drudis.2010.08.001_bib0205","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0014-2999(00)00465-9","article-title":"Evidence that atypical vasopressin V(2) receptor in inner medulla of kidney is V(1B) receptor","volume":"401","author":"Saito","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0210","doi-asserted-by":"crossref","first-page":"E566","DOI":"10.1152\/ajpendo.00148.2003","article-title":"Pancreatic vasopressin V1b receptors: characterization in In-R1-G9 cells and localization in human pancreas","volume":"285","author":"Folny","year":"2003","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2010.08.001_bib0215","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1681\/ASN.V103647","article-title":"Physiology and pathophysiology of renal aquaporins","volume":"10","author":"Nielsen","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0220","first-page":"F823","article-title":"Vasopressin effects on urea and H2O transport in inner medullary collecting duct subsegments","volume":"253","author":"Sands","year":"1987","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0225","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0022-3565(24)36848-X","article-title":"V2 receptor antagonism of DDAVP-induced release of hemostasis factors in conscious dogs","volume":"282","author":"Bernat","year":"1997","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0230","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/01.CIR.82.5.1724","article-title":"Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)","volume":"82","author":"Francis","year":"1990","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0235","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S0735-1097(83)80040-0","article-title":"Increased plasma arginine vasopressin levels in patients with congestive heart failure","volume":"1","author":"Goldsmith","year":"1983","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0240","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1056\/NEJM198107303050506","article-title":"Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure","volume":"305","author":"Szatalowicz","year":"1981","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2010.08.001_bib0245","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0735-1097(94)90001-9","article-title":"Prognostic value of neurohumoral activation in patients with an acute myocardial infarction: effect of captopril","volume":"24","author":"Rouleau","year":"1994","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0250","doi-asserted-by":"crossref","first-page":"5450","DOI":"10.1073\/pnas.94.10.5450","article-title":"Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct","volume":"94","author":"Nielsen","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.drudis.2010.08.001_bib0255","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1172\/JCI119312","article-title":"Upregulation of aquaporin-2 water channel expression in chronic heart failure rat","volume":"99","author":"Xu","year":"1997","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2010.08.001_bib0260","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0735-1097(86)80417-X","article-title":"Hemodynamic effects of infused arginine vasopressin in congestive heart failure","volume":"8","author":"Goldsmith","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0265","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s004240050772","article-title":"AVP-induced mitogenic responses of Chinese hamster ovary cells expressing human V1A or V1B receptors","volume":"437","author":"Tahara","year":"1999","journal-title":"Pflugers Arch."},{"key":"10.1016\/j.drudis.2010.08.001_bib0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0014-2999(99)00004-7","article-title":"Vasopressin increases vascular endothelial growth factor secretion from human vascular smooth muscle cells","volume":"368","author":"Tahara","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0275","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0008-6363(97)00324-6","article-title":"Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte","volume":"38","author":"Tahara","year":"1998","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2010.08.001_bib0280","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0014-2999(99)00775-X","article-title":"Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor","volume":"391","author":"Nakamura","year":"2000","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0285","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1023\/A:1006980517557","article-title":"Arginine vasopressin increases the rate of protein synthesis in isolated perfused adult rat heart via the V1 receptor","volume":"195","author":"Fukuzawa","year":"1999","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.drudis.2010.08.001_bib0290","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1097\/00005344-199712000-00010","article-title":"Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced hyperplasia and hypertrophy of cultured vascular smooth-muscle cells","volume":"30","author":"Tahara","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0295","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1024\/0369-8394.91.37.1467","article-title":"Long-term diuretic treatment in heart failure: are there differences between furosemide and torasemide?","volume":"91","author":"Spannheimer","year":"2002","journal-title":"Praxis (Bern 1994)"},{"key":"10.1016\/j.drudis.2010.08.001_bib0300","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1177\/106002809502900411","article-title":"Torsemide: a pyridine\u2013sulfonylurea loop diuretic","volume":"29","author":"Blose","year":"1995","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.drudis.2010.08.001_bib0305","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-199141010-00008","article-title":"Torasemide. A review of its pharmacological properties and therapeutic potential","volume":"41","author":"Friedel","year":"1991","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2010.08.001_bib0310","doi-asserted-by":"crossref","first-page":"104","DOI":"10.2165\/00002018-199614020-00005","article-title":"Benefits and risks of torasemide in congestive heart failure and essential hypertension","volume":"14","author":"Brater","year":"1996","journal-title":"Drug Saf."},{"key":"10.1016\/j.drudis.2010.08.001_bib0315","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1016\/j.jacc.2003.12.052","article-title":"Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure","volume":"43","author":"L\u00f3pez","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0320","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1388-9842(03)00150-8","article-title":"Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV\u2013efficacy and quality of life","volume":"5","author":"M\u00fcller","year":"2003","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0325","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/S1388-9842(02)00122-8","article-title":"Torasemide in chronic heart failure: results of the TORIC study","volume":"4","author":"Cos\u00edn","year":"2002","journal-title":"Eur. J. Heart Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0330","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0002-9343(01)00903-2","article-title":"Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure","volume":"111","author":"Murray","year":"2001","journal-title":"Am. J. Med."},{"key":"10.1016\/j.drudis.2010.08.001_bib0335","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/j.1742-1241.1998.tb08911.x","article-title":"Comparison of therapies with torasemide or furosemide in patients with congestive heart failure from a pharmacoeconomic viewpoint","volume":"52","author":"Spannheimer","year":"1998","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.drudis.2010.08.001_bib0340","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1254\/fpj.118.97","volume":"118","author":"Kido","year":"2001","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"10.1016\/j.drudis.2010.08.001_bib0345","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2165\/00003495-199549010-00009","article-title":"Torasemide. An update of its pharmacological properties and therapeutic efficacy","volume":"49","author":"Dunn","year":"1995","journal-title":"Drugs"},{"key":"10.1016\/j.drudis.2010.08.001_bib0350","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.bcp.2007.09.026","article-title":"Comparative effects of torasemide and furosemide in rats with heart failure","volume":"75","author":"Veeraveedu","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0355","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1161\/01.CIR.100.12.1311","article-title":"Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction","volume":"100","author":"Cooper","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0360","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S0735-1097(03)00765-4","article-title":"Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD)","volume":"42","author":"Domanski","year":"2003","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0365","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/j.jacc.2004.04.059","article-title":"Furosemide and the progression of left ventricular dysfunction in experimental heart failure","volume":"44","author":"McCurley","year":"2004","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0370","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000165065.82609.3D","volume":"111","author":"Klein","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0375","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.cardfail.2004.02.011","article-title":"Risk stratification after hospitalization for decompensated heart failure","volume":"10","author":"Felker","year":"2004","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0380","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/17482940701210179","article-title":"Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial","volume":"9","author":"Rossi","year":"2007","journal-title":"Acute Card. Care"},{"key":"10.1016\/j.drudis.2010.08.001_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pa.13.040173.000253","article-title":"Synthetic analogs of oxytocin and the vasopressins","volume":"13","author":"Sawyer","year":"1973","journal-title":"Annu. Rev. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0390","first-page":"87","article-title":"The development of vasopressin antagonists","volume":"43","author":"Sawyer","year":"1984","journal-title":"Fed. Proc."},{"key":"10.1016\/j.drudis.2010.08.001_bib0395","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/sj.ki.5000432","article-title":"Vasopressin receptor antagonists","volume":"69","author":"Greenberg","year":"2006","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2010.08.001_bib0400","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/S0735-1097(86)80333-3","article-title":"Contribution of vasopressin to vasoconstriction in patients with congestive heart failure: comparison with the renin\u2013angiotensin system and the sympathetic nervous system","volume":"7","author":"Creager","year":"1986","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0405","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2005.02.095","article-title":"Vasopressin antagonism in heart failure","volume":"46","author":"Goldsmith","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0410","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1172\/JCI116881","article-title":"Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men","volume":"92","author":"Ohnishi","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.drudis.2010.08.001_bib0415","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(99)00530-0","article-title":"In vivo and in vitro characterisation of a nonpeptide vasopressin V(1A) and V(2) receptor antagonist (YM087) in the rat","volume":"381","author":"Risvanis","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0420","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0014-2999(99)00379-9","article-title":"Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure","volume":"376","author":"Yatsu","year":"1999","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0425","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1043661802002062","article-title":"Effect of conivaptan, a combined vasopressin V(1a) and V(2) receptor antagonist, on vasopressin-induced cardiac and haemodynamic changes in anaesthetised dogs","volume":"46","author":"Yatsu","year":"2002","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.drudis.2010.08.001_bib0430","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0014-2999(02)02101-5","article-title":"Effect of the vasopressin receptor antagonist conivaptan in rats with heart failure following myocardial infarction","volume":"450","author":"Wada","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0435","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2004.11.022","article-title":"Intravenous administration of conivaptan hydrochloride improves cardiac hemodynamics in rats with myocardial infarction-induced congestive heart failure","volume":"507","author":"Wada","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0440","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0008-6363(02)00244-4","article-title":"Neurohormonal antagonism in heart failure; beneficial effects of vasopressin V(1a) and V(2) receptor blockade and ACE inhibition","volume":"54","author":"Naitoh","year":"2002","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2010.08.001_bib0445","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1111\/j.1476-5381.1992.tb09058.x","article-title":"Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist","volume":"105","author":"Yamamura","year":"1992","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0450","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S0008-6363(01)00315-7","article-title":"Vasopressin V2 receptor antagonists","volume":"51","author":"Wong","year":"2001","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.drudis.2010.08.001_bib0455","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3466.2007.00001.x","article-title":"Tolvaptan, an orally active vasopressin V(2)-receptor antagonist \u2013 pharmacology and clinical trials","volume":"25","author":"Miyazaki","year":"2007","journal-title":"Cardiovasc. Drug Rev."},{"key":"10.1016\/j.drudis.2010.08.001_bib0460","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/S0022-3565(24)35289-9","article-title":"Effects of the V(2)-receptor antagonist OPC-41061 and the loop diuretic furosemide alone and in combination in rats","volume":"292","author":"Hirano","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0465","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/0090-1229(90)90039-S","article-title":"A novel experimental model of giant cell myocarditis induced in rats by immunization with cardiac myosin fraction","volume":"57","author":"Kodama","year":"1990","journal-title":"Clin. Immunol. Immunopathol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0470","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.bcp.2007.11.011","article-title":"Effects of V2-receptor antagonist tolvaptan and the loop diuretic furosemide in rats with heart failure","volume":"75","author":"Veeraveedu","year":"2008","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0475","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.bcp.2007.07.027","article-title":"Effects of nonpeptide vasopressin V2 antagonist tolvaptan in rats with heart failure","volume":"74","author":"Veeraveedu","year":"2007","journal-title":"Biochem. Pharmacol."},{"issue":"Suppl. III","key":"10.1016\/j.drudis.2010.08.001_bib0480","first-page":"21","article-title":"Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure","volume":"110","author":"Onogawa","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0485","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1161\/CIRCHEARTFAILURE.109.916114","article-title":"Renal and anti-aldosterone actions of vasopressin-2 receptor antagonism and B-type natriuretic peptide in experimental heart failure","volume":"3","author":"Costello-Boerrigter","year":"2010","journal-title":"Circ. Heart Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0490","doi-asserted-by":"crossref","first-page":"3037","DOI":"10.1210\/en.2004-1590","article-title":"Therapeutic effects of tolvaptan, a potent, selective nonpeptide vasopressin V2 receptor antagonist, in rats with acute and chronic severe hyponatremia","volume":"146","author":"Miyazaki","year":"2005","journal-title":"Endocrinology"},{"key":"10.1016\/j.drudis.2010.08.001_bib0495","first-page":"F926","article-title":"Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats","volume":"269","author":"Fujita","year":"1995","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0500","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/ki.1994.265","article-title":"Therapeutic efficacy of the non-peptide AVP antagonist OPC-31260 in cirrhotic rats","volume":"46","author":"Tsuboi","year":"1994","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2010.08.001_bib0505","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/sj.bjp.0706375","article-title":"Sustained aquaretic effect of the V2-AVP receptor antagonist, RWJ-351647, in cirrhotic rats with ascites and water retention","volume":"146","author":"Ros","year":"2005","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0510","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/S0168-8278(03)00116-8","article-title":"Effect of the V1a\/V2-AVP receptor antagonist, Conivaptan, on renal water metabolism and systemic hemodynamics in rats with cirrhosis and ascites","volume":"38","author":"Fern\u00e1ndez-Varo","year":"2003","journal-title":"J. Hepatol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0515","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)38872-X","article-title":"Long-term aquaretic efficacy of a selective nonpeptide V(2)-vasopressin receptor antagonist, SR121463, in cirrhotic rats","volume":"295","author":"Jim\u00e9nez","year":"2000","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.drudis.2010.08.001_bib0520","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1111\/j.1751-0813.2000.tb10497.x","article-title":"Effects of an oral vasopressin receptor antagonist (OPC-31260) in a dog with syndrome of inappropriate secretion of antidiuretic hormone","volume":"78","author":"Fleeman","year":"2000","journal-title":"Aust. Vet. J."},{"key":"10.1016\/j.drudis.2010.08.001_bib0525","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1248\/bpb.30.91","article-title":"A novel vasopressin dual V1A\/V2 receptor antagonist, conivaptan hydrochloride, improves hyponatremia in rats with syndrome of inappropriate secretion of antidiuretic hormone (SIADH)","volume":"30","author":"Wada","year":"2007","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.drudis.2010.08.001_bib0530","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/ki.1982.216","article-title":"Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats","volume":"22","author":"Ishikawa","year":"1982","journal-title":"Kidney Int."},{"key":"10.1016\/j.drudis.2010.08.001_bib0535","doi-asserted-by":"crossref","first-page":"F502","DOI":"10.1152\/ajprenal.2000.279.3.F502","article-title":"Vasopressin-dependent upregulation of aquaporin-2 gene expression in glucocorticoid-deficient rats","volume":"279","author":"Saito","year":"2000","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0540","doi-asserted-by":"crossref","first-page":"F1135","DOI":"10.1152\/ajprenal.00356.2005","article-title":"Molecular analysis of impaired urinary diluting capacity in glucocorticoid deficiency","volume":"290","author":"Wang","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0545","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/(SICI)1520-6408(1999)24:3\/4<309::AID-DVG14>3.0.CO;2-5","article-title":"Developmental expression of urine concentration-associated genes and their altered expression in murine infantile-type polycystic kidney disease","volume":"24","author":"Gattone","year":"1999","journal-title":"Dev. Genet."},{"key":"10.1016\/j.drudis.2010.08.001_bib0550","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","article-title":"Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease","volume":"10","author":"Torres","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.drudis.2010.08.001_bib0555","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.semnephrol.2008.03.003","article-title":"Vasopressin antagonists in polycystic kidney disease","volume":"28","author":"Torres","year":"2008","journal-title":"Semin. Nephrol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0560","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1681\/ASN.2004121090","article-title":"Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat","volume":"16","author":"Wang","year":"2005","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0565","doi-asserted-by":"crossref","first-page":"40419","DOI":"10.1074\/jbc.M405079200","article-title":"Calcium restriction allows cAMP activation of the B-Raf\/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype","volume":"279","author":"Yamaguchi","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.drudis.2010.08.001_bib0570","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1681\/ASN.2006030251","article-title":"Increased water intake decreases progression of polycystic kidney disease in the PCK rat","volume":"17","author":"Nagao","year":"2006","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0575","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.drudis.2010.08.001_bib0580","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"Am. J. Nephrol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0585","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.drudis.2010.08.001_bib0590","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0595","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia","volume":"21","author":"Berl","year":"2010","journal-title":"J. Am. Soc. Nephrol."},{"issue":"Suppl. 6","key":"10.1016\/j.drudis.2010.08.001_bib0600","first-page":"S120","article-title":"Novel vasopressin V1a and V2 antagonist (conivaptan) increases serum sodium concentration in patients with hyponatremia secondary to congestive heart failure","volume":"11","author":"Verbalis","year":"2005","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0605","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1067\/mhj.2003.39","article-title":"Rationale for use of an exercise end point and design for the ADVANCE (A Dose evaluation of a Vasopressin ANtagonist in CHF patients undergoing Exercise) trial","volume":"145","author":"Russell","year":"2003","journal-title":"Am. Heart J."},{"key":"10.1016\/j.drudis.2010.08.001_bib0610","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.cardfail.2008.06.003","article-title":"Efficacy and safety of the vasopressin V1A\/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study","volume":"14","author":"Goldsmith","year":"2008","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0615","first-page":"541","article-title":"Interaction between furosemide and oral conivaptan (YM087) in patients with heart failure","volume":"22","author":"Tonkon","year":"2001","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.drudis.2010.08.001_bib0620","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0625","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.drudis.2010.08.001_bib0630","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.drudis.2010.08.001_bib0635","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.drudis.2010.08.001_bib0640","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0645","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1161\/hc4501.099313","article-title":"Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure","volume":"104","author":"Udelson","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0650","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/j.jacc.2008.08.013","article-title":"Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial","volume":"52","author":"Udelson","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0655","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.jacc.2007.01.091","article-title":"Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction","volume":"49","author":"Udelson","year":"2007","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0660","doi-asserted-by":"crossref","first-page":"F273","DOI":"10.1152\/ajprenal.00195.2005","article-title":"Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure","volume":"290","author":"Costello-Boerrigter","year":"2006","journal-title":"Am. J. Physiol. Renal Physiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0665","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.cardfail.2007.10.006","article-title":"Acute hemodynamic effects of tolvaptan, a Vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: the ECLIPSE international, multicenter, randomized, placebo-controlled trial","volume":"13","author":"Udelson","year":"2007","journal-title":"J. Card. Fail."},{"key":"10.1016\/j.drudis.2010.08.001_bib0670","unstructured":"\u201cTEMPO 3\/4 Trial\u201d Tolvaptan Efficacy and Safety in Management of Polycystic Kidney Disease and Its Outcomes (TEMPO3\/4) (http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00428948). (accessed 27 October 2009)"},{"key":"10.1016\/j.drudis.2010.08.001_bib0675","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2005.08.022","volume":"46","author":"Hunt","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.drudis.2010.08.001_bib0680","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1001\/jama.298.17.2009","article-title":"Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials","volume":"298","author":"McMurray","year":"2007","journal-title":"J. Am. Med. Assoc."},{"key":"10.1016\/j.drudis.2010.08.001_bib0685","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.drudis.2010.08.001_bib0690","unstructured":"CardioKine Inc. THE BALANCE study: treatment of hyponatremia based on lixivaptan in NYHA class III\/IV cardiac patient evaluation (http:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00578695) (accessed 27 October 2009)"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461000259X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964461000259X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:06:44Z","timestamp":1761221204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964461000259X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":138,"journal-issue":{"issue":"19-20","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S135964461000259X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2010.08.001","relation":{},"ISSN":["1359-6446"],"issn-type":[{"type":"print","value":"1359-6446"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2010.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}